未登录.png)
分享.png)
收藏分享 收藏 分享 收藏 分享 收藏 A randomized, double-blind, placebo-controlled phase III study evaluating the preventive effect of diclofenac cream on capecitabine-related hand-foot syndrome: study protocol of J-SUPPORT2401/JORTC-SUP06 (J-DIRECT)一项随机、双盲、安慰剂对照的III期研究，评估双氯芬酸乳膏对卡培他滨相关手足综合征的预防效果：J-SUPPORT2401/JORTC-SUP06（J-DIRECT）研究方案
Iimura, Yohei; Ishiguro, Hiroshi; Hashimoto, Hironobu; Nojima, Masanori; Oyamada, Shunsuke; Mori, Keita; Ariyoshi, Keisuke; Kuroda, Seiichiro; Hirakawa, Satoshi; Fujiwara, Noriko; Yokota, Tomoya; Zenda, Sadamoto; Matsuoka, Hiromichi; Boku, Narikazu 分享 收藏 A nonrandomized, single-arm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer: Japan Clinical Oncology Group study (JCOG1009/1010) (vol 24, pg 479, 2020)Takizawa, Kohei; Ono, Hiroyuki; Hasuike, Noriaki; Takashima, Atsuo; Minashi, Keiko; Boku, Narikazu; Kushima, Ryoji; Katayama, Hiroshi; Ogawa, Gakuto; Fukuda, Haruhiko; Fujisaki, Junko; Oda, Ichiro; Yano, Tomonori; Hori, Shinichiro; Doyama, Hisashi; Hirasawa, Kingo; Yamamoto, Yoshinobu; Ishihara, Ryu; Tanabe, Satoshi; Niwa, Yasumasa; Nakagawa, Masahiro; Terashima, Masanori; Muto, Manabu; Gastrointestinal Endoscopy Grp GIESG; SCSG; Japan Clin Oncol Grp 分享 收藏 Potential impact of APC mutation on survival via immune evasion through WNT signaling activation in HER2-positive gastric cancer treated with trastuzumab (tmab), nivolumab (nivo), and chemotherapyAPC基因突变通过激活WNT信号通路介导免疫逃逸，对接受曲妥珠单抗（tmab）、纳武利尤单抗（nivo）和化疗治疗的HER2阳性胃癌患者生存的影响。Wakatsuki, T.; Mashima, T.; Yamamoto, N.; Ooki, A.; Shoji, H.; Chin, K.; Ogura, M.; Kiyotani, K.; Nakayama, I.; Osumi, H.; Fukuoka, S.; Shinozaki, E.; Minashi, K.; Hara, H.; Takeuchi, K.; Seimiya, H.; Kitano, S.; Boku, N.; Yamaguchi, K.; Takahari, D. 分享 收藏 Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trialNivolumab联合化疗治疗HER2-negative，既往未治疗，不可切除，晚期或复发性胃/胃食管交界癌患者: 吸引-4随机，双盲，安慰剂对照，3期临床试验的3年随访Boku, Narikazu; Omori, Takeshi; Shitara, Kohei; Sakuramoto, Shinichi; Yamaguchi, Kensei; Kato, Ken; Kadowaki, Shigenori; Tsuji, Kunihiro; Ryu, Min-Hee; Oh, Do-Youn; Oh, Sang Cheul; Rha, Sun Young; Lee, Keun-Wook; Chung, Ik-Joo; Sym, Sun Jin; Chen, Li-Tzong; Chen, Jen-Shi; Bai, Li-Yuan; Nakada, Takashi; Hagihara, Shunsuke; Makino, Reina; Nishiyama, Eiji; Kang, Yoon-Koo 分享 收藏 Shared decision-making support program for older patients with advanced cancer using a question prompt list and geriatric assessment: A pilot randomized controlled trialObama, Kyoko; Fujimori, Maiko; Boku, Narikazu; Matsuoka, Ayumu; Mori, Keita; Okizaki, Ayumi; Miyaji, Tempei; Okamura, Masako; Majima, Yoshiyuki; Goto, Shinichi; Shimazu, Taichi; Uchitomi, Yosuke 分享 收藏 A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018GMatsumoto, Toshihiko; Yamamoto, Yoshiyuki; Kotaka, Masahito; Masuishi, Toshiki; Tsuji, Yasushi; Shoji, Hirokazu; Hirata, Kenro; Tsuduki, Takao; Makiyama, Akitaka; Izawa, Naoki; Takahashi, Naoki; Tsuda, Masahiro; Yasui, Hisateru; Ohta, Takashi; Kito, Yosuke; Otsu, Satoshi; Hironaka, Shuichi; Yamazaki, Kentaro; Boku, Narikazu; Hyodo, Ichinosuke; Yoshimura, Kenichi; Muro, Kei 分享 收藏 Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trialRivoceranib，一种VEGFR-2抑制剂，单药治疗先前治疗的晚期或转移性胃或胃食管交界处癌患者 (ANGEL研究): 一项国际，随机，安慰剂对照，3期试验Kang, Yoon-Koo; Ryu, Min-Hee; Di Bartolomeo, Maria; Chau, Ian; Yoon, Harry; Kim, Jong Gwang; Lee, Keun-Wook; Oh, Sang Chul; Takashima, Atsuo; Kryzhanivska, Anna; Chao, Yee; Evesque, Ludovic; Schenker, Michael; Mcginn, Arlo; Zhao, Yufan; Lee, Jennifer; Wyrwicz, Lucjan; Boku, Narikazu 分享 收藏 Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study)S-1/CDDP术前化疗加或不加曲妥珠单抗，然后手术治疗HER2-positive可切除的胃或食管胃结合部腺癌伴广泛淋巴结转移的随机II期临床试验的早期终点: 日本临床肿瘤学组研究JCOG1301C (触发研究)Tokunaga, Masanori; Machida, Nozomu; Mizusawa, Junki; Ito, Seiji; Yabusaki, Hiroshi; Hirao, Motohiro; Watanabe, Masaya; Imamura, Hiroshi; Kinoshita, Takahiro; Yasuda, Takushi; Hihara, Jun; Fukuda, Haruhiko; Yoshikawa, Takaki; Boku, Narikazu; Terashima, Masanori 分享 收藏 Randomized phase II study comparing neoadjuvant 5-fluorouracil/oxaliplatin/docetaxel versus docetaxel/oxaliplatin/S-1 for patients with type 4 or large type 3 gastric cancerHashimoto, Tadayoshi; Nakayama, Izuma; Ohashi, Manabu; Mizusawa, Junki; Kawachi, Hiroshi; Kita, Ryosuke; Fukuda, Haruhiko; Kurokawa, Yukinori; Boku, Narikazu; Yoshikawa, Takaki; Terashima, Masanori 分享 收藏 Randomized controlled phase III trial to investigate superiority of robot-assisted gastrectomy over laparoscopic gastrectomy for clinical stage T1-4aN0-3 gastric cancer patients (JCOG1907, MONA LISA study): a study protocolMakuuchi, Rie; Terashima, Masanori; Terada, Mitsumi; Mizusawa, Junki; Kita, Ryosuke; Tokunaga, Masanori; Omori, Takeshi; Ojima, Toshiyasu; Ehara, Kazuhisa; Watanabe, Masaya; Yanagimoto, Yoshitomo; Nunobe, Souya; Kinoshita, Takahiro; Ito, Seiji; Nishida, Yasunori; Hihara, Jun; Boku, Narikazu; Kurokawa, Yukinori; Yoshikawa, Takaki 分享 收藏 Role of tumor markers before or during chemotherapy for poorly differentiated neuroendocrine carcinomas of the digestive system: An exploratory analysis of JCOG1213Satake, T.; Morizane, C.; Machida, N.; Honma, Y.; Okusaka, T.; Boku, N.; Kato, K.; Ogawa, G.; Sano, Y.; Imaoka, H.; Kobayashi, S.; Terashima, T.; Ikeda, M.; Okano, N.; Yamaguchi, K.; Sato, T.; Mizuno, N.; Kitagawa, Y.; Terashima, M.; Ueno, M. 分享 收藏 Clinical Impact of ERBB2 copy number and tumor mutation burden (TMB) in patients with HER2-positive advanced gastric cancer treated by nivolumab (N-mab) plus trastuzumab (T-mab) and standard chemotherapyShoji, H.; Wakatsuki, T.; Takahari, D.; Yamamoto, N.; Ooki, A.; Chin, K.; Kurihara, N.; Kiyotani, K.; Mashima, T.; Ogura, M.; Nakayama, I.; Minashi, K.; Hara, H.; Shinozaki, E.; Ishizuka, N.; Kitano, S.; Seimiya, H.; Takeuchi, K.; Boku, N.; Yamaguchi, K. 分享 收藏 A phase I study of pevonedistat plus capeOX in patients with advanced gastric cancer refractory to platinum (NCCH-1811)Takahari, D.; Shoji, H.; Ooki, A.; Hirano, H.; Okita, N. T.; Nagashima, K.; Adachi, J.; Yamaguchi, K.; Kato, K.; Boku, N. 分享 收藏 APC mutation (mt.), MYC, and GATA6 amplifications (amp.) were associated with worse survival in HER2-positive advanced gastric cancer patients treated with S-1/ capecitabine plus oxaliplatin combined with trastuzumab (Tmab) and nivolumab (N-mab)Wakatsuki, T.; Takahari, D.; Yamamoto, N.; Ooki, A.; Chin, K.; Kurihara, N.; Mashima, T.; Ogura, M.; Nakayama, I.; Fukuoka, S.; Hirano, H.; Minashi, K.; Hara, H.; Kato, K.; Ishizuka, N.; Kitano, S.; Seimiya, H.; Takeuchi, K.; Boku, N.; Yamaguchi, K. 分享 收藏 The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial)Kadowaki, S.; Sakai, D.; Kawabata, R.; Hara, H.; Yasui, H.; Takahashi, M.; Hirao, M.; Imai, H.; Minashi, K.; Kawakami, T.; Satake, H.; Matsuyama, J.; Sakamoto, Y.; Sawada, K.; Kataoka, M.; Kawakami, H.; Shimokawa, T.; Boku, N.; Satoh, T. 分享 收藏 Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G)氟尿苷/替匹拉西 (FTD/TPI) 联合雷莫昔单抗 (RAM) 与氟尿苷/替匹拉西单抗治疗先前治疗的晚期胃或食管胃交界处腺癌患者的随机II期试验 (检索研究，WJOG15822G)Takahashi, Naoki; Hara, Hiroki; Nagashima, Kengo; Hirata, Kenro; Masuishi, Toshiki; Matsumoto, Toshihiko; Kawakami, Hisato; Yamazaki, Kentaro; Hironaka, Shuichi; Boku, Narikazu; Muro, Kei 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png)
OAAI
OAAI.png)
ANNALS OF ONCOLOGY